These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2529108)

  • 1. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.
    Talley NJ; Phillips SF; Haddad A; Miller LJ; Twomey C; Zinsmeister AR; Ciociola A
    Dig Dis Sci; 1989 Oct; 34(10):1511-5. PubMed ID: 2529108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.
    Talley NJ; Phillips SF; Haddad A; Miller LJ; Twomey C; Zinsmeister AR; MacCarty RL; Ciociola A
    Dig Dis Sci; 1990 Apr; 35(4):477-80. PubMed ID: 2138532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit.
    Kellow JE; Borody TJ; Phillips SF; Haddad AC; Brown ML
    Gastroenterology; 1986 Aug; 91(2):396-400. PubMed ID: 2873075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antroduodenal motility and small bowel transit during continuous intraduodenal or intragastric administration of enteral nutrition.
    Ledeboer M; Masclee AA; Coenraad M; Vecht J; Biemond I; Lamers CB
    Eur J Clin Invest; 1999 Jul; 29(7):615-23. PubMed ID: 10411668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects.
    Nelson-Piercy C; Hammond PJ; Gwilliam ME; Khandan-Nia N; Myers MJ; Ghatei MA; Bloom SR
    J Clin Endocrinol Metab; 1994 Feb; 78(2):329-36. PubMed ID: 7906279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut hormones and gastrointestinal motility in children with cystic fibrosis.
    Murphy MS; Brunetto AL; Pearson AD; Ghatei MA; Nelson R; Eastham EJ; Bloom SR; Green AA
    Dig Dis Sci; 1992 Feb; 37(2):187-92. PubMed ID: 1735334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proximal and distal gut hormone secretion in slow transit constipation.
    Penning C; Delemarre JB; Bemelman WA; Biemond I; Lamers CB; Masclee AA
    Eur J Clin Invest; 2000 Aug; 30(8):709-14. PubMed ID: 10964163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of indirect methods of estimating small bowel transit in man.
    Pressman JH; Hofmann AF; Witztum KF; Gertler SL; Steinbach JH; Stokes K; Kelts DG; Stone DM; Jones BR; Dharmsathaphorn K
    Dig Dis Sci; 1987 Jul; 32(7):689-99. PubMed ID: 3109861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of peptide YY on cephalic, gastric, and intestinal phases of gastric acid secretion and on the release of gastrointestinal hormones.
    Guo YS; Singh P; Gomez G; Greeley GH; Thompson JC
    Gastroenterology; 1987 May; 92(5 Pt 1):1202-8. PubMed ID: 3557015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers.
    Savage AP; Adrian TE; Carolan G; Chatterjee VK; Bloom SR
    Gut; 1987 Feb; 28(2):166-70. PubMed ID: 3557189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraileal carbohydrate regulates canine postprandial pancreaticobiliary secretion and upper gut motility.
    Tohno H; Sarr MG; DiMagno EP
    Gastroenterology; 1995 Dec; 109(6):1977-85. PubMed ID: 7498664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea.
    Read NW; Miles CA; Fisher D; Holgate AM; Kime ND; Mitchell MA; Reeve AM; Roche TB; Walker M
    Gastroenterology; 1980 Dec; 79(6):1276-82. PubMed ID: 7439633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans.
    Bauer FE; Zintel A; Kenny MJ; Calder D; Ghatei MA; Bloom SR
    Gastroenterology; 1989 Aug; 97(2):260-4. PubMed ID: 2472997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed mouth-caecum transit of a lactulose labelled liquid test meal in patients with steatorrhoea caused by partially treated coeliac disease.
    Spiller RC; Lee YC; Edge C; Ralphs DN; Stewart JS; Bloom SR; Silk DB
    Gut; 1987 Oct; 28(10):1275-82. PubMed ID: 3678957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.
    Dumoulin V; Dakka T; Plaisancie P; Chayvialle JA; Cuber JC
    Endocrinology; 1995 Nov; 136(11):5182-8. PubMed ID: 7588257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closing remarks. Ondansetron: effects on gastrointestinal motility.
    Lamers CB
    Scand J Gastroenterol Suppl; 1991; 188():124-6. PubMed ID: 1837938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties.
    Stott JR; Barnes GR; Wright RJ; Ruddock CJ
    Br J Clin Pharmacol; 1989 Feb; 27(2):147-57. PubMed ID: 2523720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist.
    Gore S; Gilmore IT; Haigh CG; Brownless SM; Stockdale H; Morris AI
    Aliment Pharmacol Ther; 1990 Apr; 4(2):139-44. PubMed ID: 2151757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.